Loading
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, and commercialization of innovative therapeutic proteins. The firm's pipeline includes a range of product candidates, many of which utilize its proprietary DARPin® technology. Key developments include Abicipar, a DARPin therapeutic in Phase III clinical trials for addressing neovascular wet age-related macular degeneration and diabetic macular edema. In the infectious disease space, they are advancing MP0420, a multi-specific DARPin therapeutic targeting the SARS-CoV-2 virus, and MP0423 for COVID-19 treatment. Their oncology programs feature MP0310, currently in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist designed to stimulate immune cells within tumors, which is undergoing Phase I clinical trials; and MP0274, also in Phase I, for HER2-positive cancers. Additional therapeutic candidates encompass MP0533, a CD3 T cell agent for acute myeloid leukemia, and MP0250, engineered to extend drug half-life by interacting with vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin. Molecular Partners AG has established significant partnerships and collaboration agreements with various entities, such as Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc., in addition to other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Previous close
$4.35
$0.00 · 0.00%
Regular session · ET · Market data may be delayed.
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, and commercialization of innovative therapeutic proteins. The firm's pipeline includes a range of product candidates, many of which utilize its proprietary DARPin® technology. Key developments include Abicipar, a DARPin therapeutic in Phase III clinical trials for addressing neovascular wet age-related macular degeneration and diabetic macular edema. In the infectious disease space, they are advancing MP0420, a multi-specific DARPin therapeutic targeting the SARS-CoV-2 virus, and MP0423 for COVID-19 treatment. Their oncology programs feature MP0310, currently in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist designed to stimulate immune cells within tumors, which is undergoing Phase I clinical trials; and MP0274, also in Phase I, for HER2-positive cancers. Additional therapeutic candidates encompass MP0533, a CD3 T cell agent for acute myeloid leukemia, and MP0250, engineered to extend drug half-life by interacting with vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin. Molecular Partners AG has established significant partnerships and collaboration agreements with various entities, such as Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc., in addition to other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Day range
Current $4.35
52-week range
Current $4.35
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Sell
Trim exposure — unfavorable risk-reward
Valuation
23
Expensive
Sentiment
47
Mixed
Risk
59
Elevated Risk
Momentum
39
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, and commercialization of innovative therapeutic proteins. The firm's pipeline includes a range of product candidates, many of which utilize its proprietary DARPin® technology. Key developments include Abicipar, a DARPin therapeutic in Phase III clinical trials for addressing neovascular wet age-related macular degeneration and diabetic macular edema. In the infectious disease space, they are advancing MP0420, a multi-specific DARPin therapeutic targeting the SARS-CoV-2 virus, and MP0423 for COVID-19 treatment. Their oncology programs feature MP0310, currently in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist designed to stimulate immune cells within tumors, which is undergoing Phase I clinical trials; and MP0274, also in Phase I, for HER2-positive cancers. Additional therapeutic candidates encompass MP0533, a CD3 T cell agent for acute myeloid leukemia, and MP0250, engineered to extend drug half-life by interacting with vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin. Molecular Partners AG has established significant partnerships and collaboration agreements with various entities, such as Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc., in addition to other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Day range
Current $4.35
52-week range
Current $4.35
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CHF) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | 4.97M CHF | 7.04M CHF | 189.56M CHF | 9.33M CHF |
| Cost of goods sold | 2.05M CHF | 47.5M CHF | 47.84M CHF | 50.75M CHF | 55.72M CHF |
| Gross profit | −2.05M CHF | −42.53M CHF | −40.81M CHF | 138.81M CHF | −46.39M CHF |
| Research and development | 40.19M CHF | 48.6M CHF | 48.78M CHF | 50.75M CHF | 55.72M CHF |
| Selling, general, and administrative | 14.87M CHF | 17.16M CHF | 19M CHF | 21.82M CHF | 16.91M CHF |
| Operating expenses | 50.89M CHF | 18.68M CHF | 20.3M CHF | 72.94M CHF | 72.75M CHF |
| Interest income | 1.52M CHF | 3.38M CHF | 4.28M CHF | 1.2M CHF | 108.28K CHF |
| Interest expense | 18K CHF | 25K CHF | 49K CHF | 648.12K CHF | 608.14K CHF |
| Depreciation and amortization | 2.14M CHF | 2.37M CHF | 2.42M CHF | 2.39M CHF | 2.57M CHF |
| Operating income | −58.12M CHF | −61.22M CHF | −61.11M CHF | 116.61M CHF | −63.42M CHF |
| Net income | −61.65M CHF | −54.04M CHF | −61.98M CHF | 117.85M CHF | −63.79M CHF |
Company facts updated Sep 6, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Average target
$21.00
382.76% upsidePrice history unavailable
High $29.00Average $21.00Low $13.00AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
